Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.